Health Care [ 4/12 ] | Biotechnology [ 12/75 ]
NASDAQ | Common Stock
Grifols,S. A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally.
It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.
The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services.
It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use.
In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities.
Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services.
The company was founded in 1909 and is headquartered in Barcelona, Spain.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 24, 26 | 0.29 Increased by +167.44% | 0.29 Increased by +0.80% |
| Nov 4, 25 | 0.21 Increased by +24.00% | 0.24 Decreased by -12.78% |
| Jul 28, 25 | 0.22 Increased by +46.67% | 0.28 Decreased by -21.43% |
| May 12, 25 | 0.09 Increased by +32.00% | 0.16 Decreased by -43.86% |
| Feb 26, 25 | 0.11 Decreased by -22.79% | 0.23 Decreased by -52.67% |
| Nov 7, 24 | 0.17 Increased by +54.55% | 0.24 Decreased by -29.17% |
| Jul 30, 24 | 0.15 Decreased by -9.04% | 0.21 Decreased by -28.57% |
| May 16, 24 | 0.07 Increased by +59.82% | 0.15 Decreased by -53.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 1.96 B Decreased by -0.64% | 97.33 M Increased by +41.12% | Increased by +4.96% Increased by +42.04% |
| Sep 30, 25 | 1.87 B Increased by +4.04% | 126.97 M Increased by +145.62% | Increased by +6.81% Increased by +136.08% |
| Jun 30, 25 | 1.89 B Increased by +4.03% | 117.06 M Increased by +688.78% | Increased by +6.19% Increased by +658.24% |
| Mar 31, 25 | 1.79 B Increased by +9.85% | 59.73 M Increased by +178.84% | Increased by +3.34% Increased by +153.84% |
| Dec 31, 24 | 1.98 B Increased by +11.66% | 68.97 M Increased by +23.17% | Increased by +3.49% Increased by +10.31% |
| Sep 30, 24 | 1.79 B Increased by +12.24% | 51.69 M Decreased by -13.19% | Increased by +2.88% Decreased by -22.65% |
| Jun 30, 24 | 1.82 B Increased by +9.28% | 14.84 M Decreased by -61.12% | Increased by +0.82% Decreased by -64.42% |
| Mar 31, 24 | 1.63 B Increased by +5.38% | 21.42 M Increased by +302.12% | Increased by +1.32% Increased by +291.80% |